Pharma Construct
ActiveSummary
Pharma Construct has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€1,975) and a net result of -€983. Equity is shrinking by about 117% per year across the filed financial years. Its solvency ranks better than 5% of 4,274 sector peers (NACE 74, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (low).
Financials · financial year 2025, micro format
2022 to 2025, 4 financial years
The operating result stays negative: a loss of €905 in 2025 against €1,771 in 2024; the loss shrinks.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 74, Other professional, scientific and technical activities: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital.
Peer companies
Historical observationOf the 7,639 companies that looked in July 2024 the way this one looks now, 8.8% went bankrupt within 24 months and 84.8% are still going.
- Micro
- 2 to 5 years old
- negative equity
- a loss of 10% of the balance sheet or more
A further 0.7% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: 0.5% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,474 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 7,639 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Gross operating margin9900 | €2,340 | -€1,928 | -€1,771 | -€905 | ▲ 48.9% |
| Operating profit (loss)9901 | €2,340 | -€1,928 | -€1,771 | -€905 | ▲ 48.9% |
| Financial charges65/66B | €25 | €67 | €77 | €78 | ▲ 1.9% |
| Recurring financial charges65 | €25 | €67 | €77 | €78 | ▲ 1.9% |
| Profit (loss) for the period before taxes9903 | €2,315 | -€1,996 | -€1,848 | -€983 | ▲ 46.8% |
| Income taxes67/77 | €463 | - | - | - | - |
| Profit (loss) for the period9904 | €1,852 | -€1,996 | -€1,848 | -€983 | ▲ 46.8% |
| Profit (loss) for the period to be appropriated9905 | €1,852 | -€1,996 | -€1,848 | -€983 | ▲ 46.8% |
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Assets | |||||
| Total assets20/58 | €4,569 | €2,111 | €263 | €425 | ▲ 61.5% |
| Current assets29/58 | €4,569 | €2,111 | €263 | €425 | ▲ 61.5% |
| Amounts receivable within one year40/41 | €302 | €317 | €139 | €371 | ▲ 168% |
| Other amounts receivable41 | €302 | €317 | €139 | €371 | ▲ 168% |
| Cash at bank and in hand54/58 | €4,267 | €1,794 | €125 | €53 | ▼ 57.1% |
| Equity and liabilities | |||||
| Total equity and liabilities10/49 | €4,569 | €2,111 | €263 | €425 | ▲ 61.5% |
| Equity10/15 | €2,852 | €856 | -€991 | -€1,975 | ▼ 99.2% |
| Contributions10/11 | €1,000 | €1,000 | €1,000 | €1,000 | = |
| Profit (loss) carried forward14 | €1,852 | -€144 | -€1,991 | -€2,975 | ▼ 49.4% |
| Amounts payable17/49 | €1,717 | €1,254 | €1,254 | €2,400 | ▲ 91.3% |
| Amounts payable within one year42/48 | €1,717 | €1,254 | €1,254 | €2,400 | ▲ 91.3% |
| Trade debts44 | - | - | - | €145 | - |
| Suppliers440/4 | - | - | - | €145 | - |
| Taxes, remuneration and social security45 | €463 | - | - | - | - |
| Taxes450/3 | €463 | - | - | - | - |
| Other amounts payable47/48 | €1,254 | €1,254 | €1,254 | €2,254 | ▲ 79.7% |
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €1,852 | -€1,996 | -€1,848 | -€983 | ▲ 46.8% |
| Operating cash flow (approximation) | €1,852 | -€1,996 | -€1,848 | -€983 | ▲ 46.8% |
| Change in cash | - | -€2,473 | -€1,669 | -€71 | ▲ 95.7% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (4)
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | micro format | 03-07-2026 | 2026-00252190 |
| 31-12-2024 | micro format | 24-06-2025 | 2025-00177752 |
| 31-12-2023 | micro format | 19-06-2024 | 2024-00141056 |
| 31-12-2022 | micro format | 07-08-2023 | 2023-00315805 |
Similar companies · same sector and region
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.